Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial
- PMID: 12190367
- DOI: 10.1001/jama.288.8.973
Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial
Abstract
Context: Plasma homocysteine level has been recognized as an important cardiovascular risk factor that predicts adverse cardiac events in patients with established coronary atherosclerosis and influences restenosis rate after percutaneous coronary intervention.
Objective: To evaluate the effect of homocysteine-lowering therapy on clinical outcome after percutaneous coronary intervention.
Design, setting, and participants: Randomized, double-blind placebo-controlled trial involving 553 patients referred to the University Hospital in Bern, Switzerland, from May 1998 to April 1999 and enrolled after successful angioplasty of at least 1 significant coronary stenosis (> or = 50%).
Intervention: Participants were randomly assigned to receive a combination of folic acid (1 mg/d), vitamin B12 (cyanocobalamin, 400 micro g/d), and vitamin B6 (pyridoxine hydrochloride, 10 mg/d) (n = 272) or placebo (n = 281) for 6 months.
Main outcome measure: Composite end point of major adverse events defined as death, nonfatal myocardial infarction, and need for repeat revascularization, evaluated at 6 months and 1 year.
Results: After a mean (SD) follow-up of 11 (3) months, the composite end point was significantly lower at 1 year in patients treated with homocysteine-lowering therapy (15.4% vs 22.8%; relative risk [RR], 0.68; 95% confidence interval [CI], 0.48-0.96; P =.03), primarily due to a reduced rate of target lesion revascularization (9.9% vs 16.0%; RR, 0.62; 95% CI, 0.40-0.97; P =.03). A nonsignificant trend was seen toward fewer deaths (1.5% vs 2.8%; RR, 0.54; 95% CI, 0.16-1.70; P =.27) and nonfatal myocardial infarctions (2.6% vs 4.3%; RR, 0.60; 95% CI, 0.24-1.51; P =.27) with homocysteine-lowering therapy. These findings remained unchanged after adjustment for potential confounders.
Conclusion: Homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 significantly decreases the incidence of major adverse events after percutaneous coronary intervention.
Comment in
-
Should patients with coronary disease and high homocysteine take folic acid?J Fam Pract. 2003 Jan;52(1):16-8. J Fam Pract. 2003. PMID: 12540303
-
Homocysteine-lowering therapy improved outcomes after percutaneous coronary intervention.ACP J Club. 2003 Mar-Apr;138(2):33. ACP J Club. 2003. PMID: 12614118 No abstract available.
Similar articles
-
Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial.JAMA. 2008 Aug 20;300(7):795-804. doi: 10.1001/jama.300.7.795. JAMA. 2008. PMID: 18714059 Clinical Trial.
-
Decreased rate of coronary restenosis after lowering of plasma homocysteine levels.N Engl J Med. 2001 Nov 29;345(22):1593-600. doi: 10.1056/NEJMoa011364. N Engl J Med. 2001. PMID: 11757505 Clinical Trial.
-
Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial.JAMA. 2008 May 7;299(17):2027-36. doi: 10.1001/jama.299.17.2027. JAMA. 2008. PMID: 18460663 Free PMC article. Clinical Trial.
-
Interventions for lowering plasma homocysteine levels in dialysis patients.Cochrane Database Syst Rev. 2016 May 31;2016(5):CD004683. doi: 10.1002/14651858.CD004683.pub4. Cochrane Database Syst Rev. 2016. PMID: 27243372 Free PMC article. Review.
-
Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements.Semin Thromb Hemost. 2000;26(3):341-8. doi: 10.1055/s-2000-8101. Semin Thromb Hemost. 2000. PMID: 11011852 Review.
Cited by
-
Non-linear associations of serum and red blood cell folate with risk of cardiovascular and all-cause mortality in hypertensive adults.Hypertens Res. 2023 Jun;46(6):1504-1515. doi: 10.1038/s41440-023-01249-3. Epub 2023 Mar 10. Hypertens Res. 2023. PMID: 36899181
-
Nonlinear associations of serum cobalamin with risk of all-cause and cardiovascular mortality in hypertensive adults.Hypertens Res. 2023 May;46(5):1276-1286. doi: 10.1038/s41440-023-01218-w. Epub 2023 Feb 20. Hypertens Res. 2023. PMID: 36805030
-
Supplementation with Folic Acid and Cardiovascular Outcomes in End-Stage Kidney Disease: A Multi-Institution Cohort Study.Nutrients. 2022 Oct 7;14(19):4162. doi: 10.3390/nu14194162. Nutrients. 2022. PMID: 36235814 Free PMC article.
-
Prevalence of hyperhomocysteinemia (HHcy) and its major determinants among hypertensive patients over 35 years of age.Eur J Clin Nutr. 2022 Apr;76(4):616-623. doi: 10.1038/s41430-021-00983-6. Epub 2021 Aug 30. Eur J Clin Nutr. 2022. PMID: 34462555
-
The Role of Oxidative Stress Markers in Predicting Acute Thrombotic Occlusion of Haemodialysis Vascular Access and Progressive Stenotic Dysfunction Demanding Angioplasty.Antioxidants (Basel). 2021 Apr 8;10(4):569. doi: 10.3390/antiox10040569. Antioxidants (Basel). 2021. PMID: 33917703 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous